Several mTOR/PI3K dual inhibitors have been reported, many of which have been tested on AML (Figure 3) [44]; interestingly, cellular studies on primary blasts collected from AML patients evidenced that high PI3K signaling was associated with resistant samples, and dual PI3K/mTOR inactivation was proven to be cytotoxic also to leukemia-initiating cells [45]. The gene discussed is MTOR; the disease is leukemia.